Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Trivedi, Palak
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis	Completed	2	62	Europe, Canada, US, RoW	EP547, Placebo	Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.	Pruritus	07/24	09/24
SPRING, NCT04595825 / 2019-002945-39: CM-101 in PSC Patients -The Study	Active, not recruiting	2	68	Europe, US, RoW	Anti-human CCL24 monoclonal antibody (CM-101), Placebo	ChemomAb Ltd., ChemomAb Ltd	Primary Sclerosing Cholangitis	09/24	09/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25